Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2012
10/18/2012US20120264775 Oligomer-Opioid Agonist Conjugates
10/18/2012US20120264767 Stable pharmaceutical composition of freeze-dried tetrodotoxin powder
10/18/2012US20120264765 Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis
10/18/2012US20120264761 Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators
10/18/2012US20120264756 Phosphatidylcholine Transfer Protein Inhibitors
10/18/2012US20120264755 Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase
10/18/2012US20120264753 Novel 1-(biphenyl-4-yl-methyl)-1h-imidazole derivative and pharmaceutical product containing same
10/18/2012US20120264749 Morpholine-spirocyclic piperidine amides as modulators of ion channels
10/18/2012US20120264748 Diaza-spiro[5.5]undecanes
10/18/2012US20120264747 Triazolopyridine jak inhibitor compounds and methods
10/18/2012US20120264743 Crystalline forms of (r)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1h-3-benzazepine hydrochloride
10/18/2012US20120264742 Pharmaceutical composition for external use
10/18/2012US20120264736 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
10/18/2012US20120264732 Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
10/18/2012US20120264730 Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
10/18/2012US20120264725 Substituted porphyrins
10/18/2012US20120264719 Dosage regimen of an s1p receptor modulator
10/18/2012US20120264716 Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
10/18/2012US20120264715 Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
10/18/2012US20120264714 Boron-containing small molecules as anti-inflammatory agents
10/18/2012US20120264706 Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
10/18/2012US20120264703 Methods And Compositions For The Treatment Of Anxiety Disorders, Including Post Traumatic Stress Disorder (PTSD) And Related Central Nervous System (CNS) Disorders.
10/18/2012US20120264701 Use of d-ribose for fatigued subjects
10/18/2012US20120264698 Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
10/18/2012US20120264693 Compounds acting as peptide gap junction modulators, and uses thereof
10/18/2012US20120264682 Tissue protective peptides and uses thereof
10/18/2012US20120264676 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
10/18/2012US20120263804 Essential element extractor
10/18/2012US20120263798 Body Aqua
10/18/2012US20120263797 Implantable polymer for bone and vascular lesions
10/18/2012US20120263795 Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
10/18/2012US20120263791 Fomulation comprising 1 h-quinazoline-2, 4-dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof
10/18/2012US20120263790 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/18/2012US20120263789 Delayed release rasagiline formulation
10/18/2012US20120263788 Controlled release hydrocodone formulations
10/18/2012US20120263765 Agents from cells
10/18/2012US20120263764 Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
10/18/2012US20120263761 Shelf stable pharmaceutical depot
10/18/2012US20120263760 Novel formulation of metaxalone
10/18/2012US20120263733 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
10/18/2012US20120263718 Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
10/18/2012US20120263712 Pyrrolidine-1,2-dicarboxamide derivatives
10/18/2012US20120263698 Treatment of Neurodegenerative Disease
10/18/2012US20120263695 Composition having strains of lactobacillus fermentum
10/18/2012US20120263681 Composition comprising cell and biocompatible polymer
10/18/2012US20120263657 Promoting Whole Body Health
10/18/2012US20120263648 Rna nanoparticles and nanotubes
10/18/2012US20120263646 Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
10/18/2012US20120263644 Treatment and diagnosis of inflammatory disorders and hiv
10/18/2012DE102011016875A1 Zubereitung enthaltend DISC1 und/oder mindestens ein DISC1-Fragment zur Anwendung bei der therapeutischen Behandlung des menschlichen oder tierischen Körpers Preparation comprising DISC1 and / or at least one DISC1 fragment for use in the therapeutic treatment of the human or animal body
10/18/2012CA2833159A1 N-acetyl beta alanine methods of use
10/18/2012CA2832817A1 Parp inhibitors for the treatment of cipn
10/18/2012CA2832704A1 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
10/18/2012CA2832650A1 Novel pyrazole derivative
10/18/2012CA2832473A1 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions, and their use
10/18/2012CA2832467A1 1,3 oxazines as bace1 and/or bace2 inhibitors
10/18/2012CA2831606A1 Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
10/17/2012EP2511283A1 N6-substituted adenosine derivatives, n6-substituted adenine derivatives and uses thereof
10/17/2012EP2511269A1 Fused heterocyclic compound having amino group
10/17/2012EP2511268A1 Oxazine derivative
10/17/2012EP2511267A1 3-((n-acylated aminoacyl)amino)pyrazoles as inhibitors of beta-amyloid peptide production useful for the treatment of alzheimer's disease
10/17/2012EP2510927A2 Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
10/17/2012EP2509983A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
10/17/2012EP2509982A1 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
10/17/2012EP2509978A1 Azocyclic inhibitors of fatty acid amide hydrolase
10/17/2012EP2509961A1 Imidazolidinedione derivatives
10/17/2012EP2509953A2 Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
10/17/2012EP2509947A1 Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same
10/17/2012EP2509940A2 Amyloid binding agents
10/17/2012EP2509939A2 Novel n-benzylamide substitued derivatives of 2-(acylamido)acetic acid and 2-(acy-lamido) propionic acids: potent neurological agents
10/17/2012EP2509616A1 Bche albumin fusions for the treatment of cocaine abuse
10/17/2012EP2509591A1 Methods and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
10/17/2012CN1922171B Pyrimidine derivative
10/17/2012CN102741277A IFN[gamma]inhibitors in the treatment of motoneuron diseases
10/17/2012CN102741264A Prostate specific membrane antigen inhibitors
10/17/2012CN102741250A Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors
10/17/2012CN102741249A Hetaryl-[1,8]naphthyridine derivatives
10/17/2012CN102741245A Benzoimidazole compounds and uses thereof
10/17/2012CN102741240A Pyrimidine compounds as delta opioid receptor modulators
10/17/2012CN102741239A Bicyclic compounds as alpha4beta2 nicotinic acetylcholine receptor ligands
10/17/2012CN102741220A New aminotetraline derivatives
10/17/2012CN102740888A Antibodies to IL-6 and use there
10/17/2012CN102740860A Read through inducer, and therapeutic agent for nonsense-mutation-type genetic diseases
10/17/2012CN102740848A Tetrahydro-pyran derivatives against neurological illnesses
10/17/2012CN102740844A Combination of droloxifene and clopidogrel
10/17/2012CN102740842A Formulations, salts and polymorphs of transnorsertraline and uses thereof
10/17/2012CN102731574A Thienopyridine alpha-amino benzylphosphonate, preparation method and application thereof
10/17/2012CN102731522A Paeoniflorin compound with inhibitory activity against abnormal expression of cyclooxygenase-2, its preparation method and application
10/17/2012CN102731499A Lactam compounds and their use as pharmaceuticals
10/17/2012CN102731468A Derivatives of aromatic propylene natural products, and preparation method and usage thereof
10/17/2012CN102731418A 1-substituted-1H-1,2,4-triazole-formamide derivatives, preparation and application thereof
10/17/2012CN102731413A Urea compound and its preparation method, intermediate and use
10/17/2012CN102731411A Preparation of 4-alkyl-6-aryl-3,4-dihydropyrimidine-2-thioketone and application of same as antidepressant drug
10/17/2012CN102731379A N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators
10/17/2012CN102731308A Method for preparing salvianolic acid A bulk drug
10/17/2012CN102727896A D-amino-acid oxidase inhibitor for preventing and/or reversing opioid tolerance
10/17/2012CN102727895A Pharmaceutical composition for targeting treatment of intractable epilepsy
10/17/2012CN102727870A Agent for prophylaxis of reflex sympathetic dystrophy after cerebral apoplexy
10/17/2012CN102727864A Novel application of polypeptide GluR2-3Y
10/17/2012CN102727863A Combined drug of compound fermented Cordyceps sinensis powder and ginsenoside Rg1
1 ... 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 ... 1833